World's newest drug-eluting stent implanted at the Methodist DeBakey Heart & Vascular CenterHouston, TX - 3/12/2008
A more flexible drug-eluting stent studied in clinical trials at the Methodist DeBakey Heart & Vascular Center has been approved by the FDA, and Methodist physicians were the first in Houston to implant the new device.
The design of the new stent, the first approved by the FDA in four years, allows it to be placed in hard to reach blockages .Research conducted at Methodist was pivotal in the Phase 3 trial that led to FDA approval of the stent.
In February Medtronic’s Endeavor stent received FDA approval for treatment of coronary artery disease, which affects 13 million Americans and is the country’s leading cause of death.
Stents are tiny wire mesh tubes used to prop open coronary arteries to restore blood flow to the heart. Drug-eluting stents deliver medication to the artery wall to reduce the chance that the artery will narrow again and require a repeat procedure.
Methodist cardiologists have been pioneers in the research and development of coronary stents, and some of these first stents were implanted at Methodist 20 years ago. Since then, more than 100,000 stents have been used to open arteries in patients at Methodist. More recent research conducted at Methodist over the past five to 10 years has also helped fine-tune treatment for patients who have drug-eluting stents, making post treatment safer and more effective with the use of anti-platelet therapy.
About the Endeavor study
For more information on the Methodist DeBakey Heart & Vascular Center, see www.debakeyheartcenter.com.